Cargando…

Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11

BACKGROUND: Gastrointestinal (GI) events are the most frequent treatment-emergent adverse events (TEAEs) reported for glucagon-like peptide-1 receptor agonist therapies. This post hoc analysis of the AWARD-11 phase 3 trial assessed the GI tolerability of dulaglutide at once-weekly doses of 1.5, 3.0,...

Descripción completa

Detalles Bibliográficos
Autores principales: Van, Joanna, Frias, Juan P., Bonora, Enzo, Raha, Sohini, Meyer, Jarrett, Jung, Heike, Cox, David, Konig, Manige, Peleshok, Jennifer, Bethel, M. Angelyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479017/
https://www.ncbi.nlm.nih.gov/pubmed/34514554
http://dx.doi.org/10.1007/s13300-021-01140-9
_version_ 1784576158482825216
author Van, Joanna
Frias, Juan P.
Bonora, Enzo
Raha, Sohini
Meyer, Jarrett
Jung, Heike
Cox, David
Konig, Manige
Peleshok, Jennifer
Bethel, M. Angelyn
author_facet Van, Joanna
Frias, Juan P.
Bonora, Enzo
Raha, Sohini
Meyer, Jarrett
Jung, Heike
Cox, David
Konig, Manige
Peleshok, Jennifer
Bethel, M. Angelyn
author_sort Van, Joanna
collection PubMed
description BACKGROUND: Gastrointestinal (GI) events are the most frequent treatment-emergent adverse events (TEAEs) reported for glucagon-like peptide-1 receptor agonist therapies. This post hoc analysis of the AWARD-11 phase 3 trial assessed the GI tolerability of dulaglutide at once-weekly doses of 1.5, 3.0, and 4.5 mg. METHODS: The AWARD-11 trial randomized patients to once-weekly dulaglutide 1.5 mg (n = 612), 3.0 mg (n = 616), or 4.5 mg (n = 614) for 52 weeks. Patients started on dulaglutide 0.75 mg for 4 weeks before escalating stepwise every 4 weeks until the final randomized dose was reached. This study analyzes the onsets, incidences, prevalences, and severities of nausea, vomiting, and diarrhea events reported through 52 weeks. RESULTS: The highest incidences of nausea (≤ 8%), vomiting (≤ 2%), and diarrhea (≤ 4%) were primarily observed soon after the initiation of dulaglutide treatment at 0.75 mg. Incidence then declined throughout the remainder of the study, even with dose escalation to 1.5, 3.0, and 4.5 mg. Most of these GI TEAEs were mild to moderate in severity, with severe nausea, vomiting, or diarrhea events occurring in ≤ 0.6% of patients. Treatment discontinuation due to nausea was low across treatment groups (≤ 1.5%). CONCLUSIONS: The tolerability profiles of dulaglutide 3.0 mg and 4.5 mg were consistent with that of the 1.5-mg dose. Patients experiencing GI events were most likely to do so within 2 weeks of treatment initiation, and few patients experienced a new GI event after escalating to the 3.0-mg or 4.5-mg dose. Severe events were infrequent, and when they did occur, no relationship with dose at time of event was observed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13300-021-01140-9.
format Online
Article
Text
id pubmed-8479017
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-84790172021-10-08 Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11 Van, Joanna Frias, Juan P. Bonora, Enzo Raha, Sohini Meyer, Jarrett Jung, Heike Cox, David Konig, Manige Peleshok, Jennifer Bethel, M. Angelyn Diabetes Ther Original Research BACKGROUND: Gastrointestinal (GI) events are the most frequent treatment-emergent adverse events (TEAEs) reported for glucagon-like peptide-1 receptor agonist therapies. This post hoc analysis of the AWARD-11 phase 3 trial assessed the GI tolerability of dulaglutide at once-weekly doses of 1.5, 3.0, and 4.5 mg. METHODS: The AWARD-11 trial randomized patients to once-weekly dulaglutide 1.5 mg (n = 612), 3.0 mg (n = 616), or 4.5 mg (n = 614) for 52 weeks. Patients started on dulaglutide 0.75 mg for 4 weeks before escalating stepwise every 4 weeks until the final randomized dose was reached. This study analyzes the onsets, incidences, prevalences, and severities of nausea, vomiting, and diarrhea events reported through 52 weeks. RESULTS: The highest incidences of nausea (≤ 8%), vomiting (≤ 2%), and diarrhea (≤ 4%) were primarily observed soon after the initiation of dulaglutide treatment at 0.75 mg. Incidence then declined throughout the remainder of the study, even with dose escalation to 1.5, 3.0, and 4.5 mg. Most of these GI TEAEs were mild to moderate in severity, with severe nausea, vomiting, or diarrhea events occurring in ≤ 0.6% of patients. Treatment discontinuation due to nausea was low across treatment groups (≤ 1.5%). CONCLUSIONS: The tolerability profiles of dulaglutide 3.0 mg and 4.5 mg were consistent with that of the 1.5-mg dose. Patients experiencing GI events were most likely to do so within 2 weeks of treatment initiation, and few patients experienced a new GI event after escalating to the 3.0-mg or 4.5-mg dose. Severe events were infrequent, and when they did occur, no relationship with dose at time of event was observed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13300-021-01140-9. Springer Healthcare 2021-09-12 2021-10 /pmc/articles/PMC8479017/ /pubmed/34514554 http://dx.doi.org/10.1007/s13300-021-01140-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Van, Joanna
Frias, Juan P.
Bonora, Enzo
Raha, Sohini
Meyer, Jarrett
Jung, Heike
Cox, David
Konig, Manige
Peleshok, Jennifer
Bethel, M. Angelyn
Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
title Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
title_full Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
title_fullStr Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
title_full_unstemmed Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
title_short Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
title_sort gastrointestinal tolerability of once-weekly dulaglutide 3.0 mg and 4.5 mg: a post hoc analysis of the incidence and prevalence of nausea, vomiting, and diarrhea in award-11
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479017/
https://www.ncbi.nlm.nih.gov/pubmed/34514554
http://dx.doi.org/10.1007/s13300-021-01140-9
work_keys_str_mv AT vanjoanna gastrointestinaltolerabilityofonceweeklydulaglutide30mgand45mgaposthocanalysisoftheincidenceandprevalenceofnauseavomitinganddiarrheainaward11
AT friasjuanp gastrointestinaltolerabilityofonceweeklydulaglutide30mgand45mgaposthocanalysisoftheincidenceandprevalenceofnauseavomitinganddiarrheainaward11
AT bonoraenzo gastrointestinaltolerabilityofonceweeklydulaglutide30mgand45mgaposthocanalysisoftheincidenceandprevalenceofnauseavomitinganddiarrheainaward11
AT rahasohini gastrointestinaltolerabilityofonceweeklydulaglutide30mgand45mgaposthocanalysisoftheincidenceandprevalenceofnauseavomitinganddiarrheainaward11
AT meyerjarrett gastrointestinaltolerabilityofonceweeklydulaglutide30mgand45mgaposthocanalysisoftheincidenceandprevalenceofnauseavomitinganddiarrheainaward11
AT jungheike gastrointestinaltolerabilityofonceweeklydulaglutide30mgand45mgaposthocanalysisoftheincidenceandprevalenceofnauseavomitinganddiarrheainaward11
AT coxdavid gastrointestinaltolerabilityofonceweeklydulaglutide30mgand45mgaposthocanalysisoftheincidenceandprevalenceofnauseavomitinganddiarrheainaward11
AT konigmanige gastrointestinaltolerabilityofonceweeklydulaglutide30mgand45mgaposthocanalysisoftheincidenceandprevalenceofnauseavomitinganddiarrheainaward11
AT peleshokjennifer gastrointestinaltolerabilityofonceweeklydulaglutide30mgand45mgaposthocanalysisoftheincidenceandprevalenceofnauseavomitinganddiarrheainaward11
AT bethelmangelyn gastrointestinaltolerabilityofonceweeklydulaglutide30mgand45mgaposthocanalysisoftheincidenceandprevalenceofnauseavomitinganddiarrheainaward11